Active versus passive anti-cytokine antibody therapy against cytokine-associated chronic diseases.
Current therapeutic vaccine trials in major chronic diseases including AIDS, cancer, allergy and autoimmunity, target antigenic pathogens but not the pathogenic stromal cytokines which can be major sources of histopathologic processes. Considering that the limited efficacy of these vaccines has been ascribed to local pathogen-induced cytokine dysfunction, we propose to antagonize pathogenic cytokine(s) by high affinity neutralizing auto-Abs triggered by specific anti-cytokine vaccines. As anticipated by theoretical considerations, animal experiments and initial clinical trials showed that anti-cytokine immunization was safe, well tolerated and triggered transient high titers Abs neutralizing pathogenic cytokines but, in contrast to conventional vaccines, no relevant cellular response was observed. Advantages of active versus passive anti-cytokine Ab therapy, particularly for long-term treatments, as those required in AIDS, cancer, allergy and autoimmunity include greater ease of maintaining high Ab titers, lack of anti-antibody responses and low cost.
Zagury
D
D
Université Pierre et Marie Curie, 15 rue de l'Ecole de Médecine, 75006, Paris, France.
Le Buanec
H
H
Bizzini
B
B
Burny
A
A
Lewis
G
G
Gallo
R C
RC
D000163:Acquired Immunodeficiency Syndrome / Q000628:therapy*; D000818:Animals; D000906:Antibodies / Q000378:metabolism; D001327:Autoimmune Diseases / Q000628:therapy*; D001402:B-Lymphocytes / Q000378:metabolism; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000502:physiology* / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D006967:Hypersensitivity / Q000628:therapy*; D008954:Models, Biological; D009369:Neoplasms / Q000628:therapy*
D000906:Antibodies; D016207:Cytokines